Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 2 of 2: Calculated dose response metrics - Dataset (ID:20344)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Primary Target | Pathway | GR50 | GRmax | GR_AOC | Death_AUC | GR Hill Coefficient | GEC50 | GR r2 |
---|---|---|---|---|---|---|---|---|---|---|
HCC1419 | Alpelisib | PI3Ka | PI3K/mTOR | 0.66882 | -0.0020 | 0.3558 | 0.0157 | 0.3922 | 11.0132 | 0.94051 |
HCC1419 | Taselisib | PI3Ka, g, d | PI3K/mTOR | 0.0091784 | -0.4046 | 0.8523 | 0.0945 | 0.5809 | 0.022714 | 0.98223 |
HCC1419 | TGX221 | PI3Kb | PI3K/mTOR | Inf | 0.7941 | -0.0049 | 0.0002 | 5.0000 | 3.889 | 0.79312 |
HCC1419 | Torin2 | mTOR/ATM/ATR | PI3K/mTOR | 0.0054867 | -0.3722 | 0.6345 | 0.0796 | 0.8272 | 0.0093689 | 0.98036 |
HCC1419 | Everolimus | mTOR1 | PI3K/mTOR | Inf | 0.1803 | 0.7242 | 0.0249 | 0.0000 | Inf | 0.37602 |
HCC1419 | INK-128 | mTORC1/2 | PI3K/mTOR | 0.0047477 | -0.1472 | 0.7635 | 0.0603 | 1.3112 | 0.0056144 | 0.99448 |
HCC1419 | PF-4708671 | p70S6K | PI3K/mTOR | 5.2795 | 0.3488 | 0.1117 | -0.0019 | 1.0898 | 4.6502 | 0.97858 |
HCC1419 | Buparlisib | pan PI3K | PI3K/mTOR | 0.39623 | -0.4961 | 0.4499 | 0.0745 | 0.8204 | 1.2651 | 0.99188 |
HCC1419 | Pictilisib | pan PI3K | PI3K/mTOR | 0.17196 | -0.2103 | 0.5118 | 0.0340 | 0.5444 | 0.61152 | 0.99425 |
HCC1419 | Ceritinib | ALK | RTK | 2.6149 | -0.8670 | 0.2083 | 0.0855 | 2.5745 | 4.0066 | 0.99248 |
HCC1419 | Neratinib | EGFR/HER2 | RTK | 0.0011485 | -0.5015 | 0.9927 | 0.1818 | 0.5367 | 0.0038194 | 0.97246 |
HCC1419 | Tivantinib | MET | RTK | 0.47955 | 0.1634 | 0.2618 | 0.0408 | 2.6512 | 0.40663 | 0.98985 |
HCC1419 | Cediranib | VEGFR/cKIT | RTK | 5.0599 | -0.0329 | 0.0545 | 0.0124 | 4.9952 | 5.1984 | 0.99032 |
HCC1419 | Cabozantinib | VEGFR2/MET | RTK | 10.7779 | 0.6224 | -0.0111 | -0.0016 | 5.0000 | 12.9768 | 0.90031 |
HCC1500 | Abemaciclib | CDK4/6 | Cell cycle | 0.53346 | 0.2196 | 0.3452 | -0.0085 | 0.4860 | 0.1477 | 0.84102 |
HCC1500 | Palbociclib | CDK4/6 | Cell cycle | Inf | 0.5744 | 0.1570 | 0.0053 | 2.6346 | 0.039317 | 0.93709 |
HCC1500 | AZD7762 | CHK1/2 | Cell cycle | 0.035943 | -0.2559 | 0.6218 | 0.1217 | 1.0434 | 0.037616 | 0.91391 |
HCC1500 | Volasertib | PLK | Cell cycle | 0.011592 | 0.2861 | 0.3454 | 0.0484 | 5.0000 | 0.0099361 | 0.97732 |
HCC1500 | Dinaciclib | pan CDK | Cell cycle | 0.013792 | -0.5720 | 0.6616 | 0.1978 | 2.3762 | 0.018927 | 0.99749 |
HCC1500 | Cisplatin | Chemo | Chemotherapy | 3.4531 | 0.2076 | 0.1210 | -0.0094 | 5.0000 | 3.1071 | 0.92762 |
HCC1500 | Doxorubicin | Chemo | Chemotherapy | 0.016258 | -0.7134 | 0.7518 | 0.1833 | 0.7212 | 0.058468 | 0.98572 |
HCC1500 | Taxol | Chemo | Chemotherapy | 0.0038131 | -0.0589 | 0.6182 | 0.1433 | 1.8138 | 0.0038924 | 0.96247 |
HCC1500 | Topotecan | Topo I | Chemotherapy | 0.0054632 | -0.8011 | 1.2171 | 0.1857 | 0.7137 | 0.022012 | 0.99509 |
HCC1500 | Etoposide | Topo II | Chemotherapy | 1.4287 | -0.0766 | 0.2499 | -0.0148 | 1.3319 | 1.7871 | 0.95725 |
HCC1500 | Dasatinib | BCR/ABL | MAPK/nRTK | 0.0034818 | -0.1594 | 0.9249 | 0.0829 | 0.7537 | 0.0052374 | 0.99634 |